Literature DB >> 2913289

Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on lipid synthesis and lipogenic enzymes in the rat.

M R Lakshman1, S J Chirtel, L L Chambers, P J Coutlakis.   

Abstract

A single i.p. administration of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) caused within 1 wk of exposure a dose-dependent progressive inhibition of liver fatty acid synthetic rate with concomitant decreases in hepatic fatty acid synthetase and acetylcoenzyme A carboxylase activities. Similarly, hepatic cholesterol synthetic rate was markedly inhibited with increasing dosage of TCDD, although the corresponding decrease in 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity was of lesser magnitude. Linear regression analyses of the reciprocals of the responses versus the dose revealed that the TCDD concentration which caused 50% inhibition of the activities of various lipogenic enzymes and of lipid synthetic rates ranged from 11 to 20 micrograms/kg (34-67 nM) with an average of 15 micrograms/kg (47 nM). Hepatic cholesterol synthesis seemed to be more sensitive to inhibition than fatty acid synthesis whether it was based on TCDD dosage or duration of exposure. The degree of inhibition of all the above parameters except fatty acid synthesis in liver and adipose tissues increased from 1 to 2 wk of exposure but was less pronounced after 4 wk exposure. Significantly, the adipose tissue was found to be more sensitive than the liver with respect to inhibition of fatty acid synthesis by increasing dosage of TCDD. Thus, the biochemical mechanism of loss of adipose mass caused by TCDD exposure may well be mediated by strong inhibition of lipid synthesis in the adipose tissue coupled with increased mobilization of depot fat.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2913289

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

1.  Alterations of hepatic acetyl-CoA carboxylase by 2,3,7,8-tetrachlorodibenzo-p-dioxin.

Authors:  J M McKim; K Marien; H W Schaup; D P Selivonchick
Journal:  Lipids       Date:  1991-07       Impact factor: 1.880

2.  TCDD-elicited effects on liver, serum, and adipose lipid composition in C57BL/6 mice.

Authors:  Michelle Manente Angrish; Claudia Yvette Dominici; Timothy Richard Zacharewski
Journal:  Toxicol Sci       Date:  2012-09-13       Impact factor: 4.849

3.  Comparative metabolomic and genomic analyses of TCDD-elicited metabolic disruption in mouse and rat liver.

Authors:  Agnes L Forgacs; Michael N Kent; Meghan K Makley; Bryan Mets; Nicholas DelRaso; Gary L Jahns; Lyle D Burgoon; Timothy R Zacharewski; Nicholas V Reo
Journal:  Toxicol Sci       Date:  2011-09-29       Impact factor: 4.849

4.  Nrf2 protects against 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-induced oxidative injury and steatohepatitis.

Authors:  Hong Lu; Wei Cui; Curtis D Klaassen
Journal:  Toxicol Appl Pharmacol       Date:  2011-08-06       Impact factor: 4.219

5.  Lipidomic Evaluation of Aryl Hydrocarbon Receptor-Mediated Hepatic Steatosis in Male and Female Mice Elicited by 2,3,7,8-Tetrachlorodibenzo-p-dioxin.

Authors:  Rance Nault; Kelly A Fader; Todd A Lydic; Timothy R Zacharewski
Journal:  Chem Res Toxicol       Date:  2017-03-20       Impact factor: 3.739

6.  An untargeted multi-technique metabolomics approach to studying intracellular metabolites of HepG2 cells exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin.

Authors:  Ainhoa Ruiz-Aracama; Ad Peijnenburg; Jos Kleinjans; Danyel Jennen; Joost van Delft; Caroline Hellfrisch; Arjen Lommen
Journal:  BMC Genomics       Date:  2011-05-20       Impact factor: 3.969

7.  Integrating transcriptomics and metabonomics to unravel modes-of-action of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in HepG2 cells.

Authors:  Danyel Jennen; Ainhoa Ruiz-Aracama; Christina Magkoufopoulou; Ad Peijnenburg; Arjen Lommen; Joost van Delft; Jos Kleinjans
Journal:  BMC Syst Biol       Date:  2011-08-31

Review 8.  The Aryl Hydrocarbon Receptor in Energy Balance: The Road from Dioxin-Induced Wasting Syndrome to Combating Obesity with Ahr Ligands.

Authors:  Nathaniel G Girer; Craig R Tomlinson; Cornelis J Elferink
Journal:  Int J Mol Sci       Date:  2020-12-23       Impact factor: 6.208

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.